The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
暂无分享,去创建一个
[1] Joyce Nelson,et al. Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys , 2000, Pharmaceutical Research.
[2] M. Graham. Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.
[3] Francesco M Veronese,et al. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. , 2002, Advanced drug delivery reviews.
[4] R. Matus,et al. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma , 1987, Cancer.
[5] Y. Byun,et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. , 2005, Bioconjugate chemistry.
[6] A. Tolcher,et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Hershfield,et al. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. , 1995, Clinical immunology and immunopathology.
[8] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[9] Darin J. Smith,et al. A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. , 2007, Endocrinology.
[10] J. Stadler,et al. PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies , 2007, Drug Metabolism and Disposition.
[11] Yasuo Yoshioka,et al. Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.
[12] F. Izzo,et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis , 2007, Journal of gastroenterology and hepatology.
[13] R. Moots,et al. CDP-870 (certolizumab) in rheumatoid arthritis , 2005, Expert opinion on biological therapy.
[14] M. Keating,et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.
[15] A. Whitty,et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. , 2006, Bioconjugate chemistry.
[16] M. Tsan,et al. Polyethylene glycol-conjugated superoxide dismutase protects rats against oxygen toxicity. , 1993, Journal of applied physiology.
[17] J. Hoofnagle,et al. Peginterferon and ribavirin for chronic hepatitis C. , 2006, The New England journal of medicine.
[18] E. Herrmann,et al. Pharmacokinetics of Peginterferons , 2003, Seminars in liver disease.
[19] Y. Ikada,et al. Comparison of Body Distribution of Poly(vinyl alcohol) with Other Water‐soluble Polymers after Intravenous Administration , 1995, The Journal of pharmacy and pharmacology.
[20] M. Hershfield,et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. , 2007, Arthritis and rheumatism.
[21] S Foser,et al. Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers. , 2003, The pharmacogenomics journal.
[22] F. Davis,et al. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. , 1980, Research communications in chemical pathology and pharmacology.
[23] J. A. Scarlett,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.
[24] D. Cutler,et al. Pegylated IFNs for chronic hepatitis C: an update , 2005, Expert opinion on drug delivery.
[25] E. C. Stevens,et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. , 2002, Endocrine reviews.
[26] M. Grace,et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[27] Lei Xie,et al. Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b , 2001 .
[28] G. Jayson,et al. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis , 2006, Expert opinion on therapeutic targets.
[29] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[30] R. Hoffman,et al. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent. , 2006, Cancer research.
[31] M. Bentley,et al. Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.
[32] C. White,et al. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. , 1988, The Journal of biological chemistry.
[33] J. Hoofnagle,et al. Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.
[34] M. Hershfield,et al. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. , 2001, Journal of the American Society of Nephrology : JASN.
[35] F. Pang,et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.
[36] N. Waugh,et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.
[37] Zhi-xin Xu,et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.
[38] Y. Tsutsumi,et al. Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity , 1995 .
[39] R. Shorr,et al. Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. , 1996, Artificial cells, blood substitutes, and immobilization biotechnology.
[40] S. Oh,et al. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[41] I. Holdaway. Treatment of Acromegaly , 2004, Hormone Research in Paediatrics.
[42] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[43] S. W. Kim,et al. Effects of PEG conjugation on insulin properties. , 2002, Advanced drug delivery reviews.
[44] L. Gold,et al. Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.
[45] F. Veronese,et al. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. , 2005, Biomacromolecules.
[46] D. Baker,et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. , 2001, The Journal of pharmacology and experimental therapeutics.
[47] B. Dolinski,et al. Design, Synthesis, and Analysis of a Polyethelene Glycol-Modified (PEGylated) Small Molecule Inhibitor of Integrin α4β1 with Improved Pharmaceutical Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.
[48] M. Hershfield,et al. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. , 1998, Seminars in hematology.
[49] S Davis,et al. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. , 1981, Clinical and experimental immunology.
[50] G. Molineux. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). , 2004, Current pharmaceutical design.
[51] A. P. Chapman,et al. PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.
[52] J. Bomalaski,et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. , 2002, The Journal of rheumatology.
[53] Darin J. Smith,et al. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. , 2005, Bioconjugate chemistry.
[54] M. Bentley,et al. 727 POSTER PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG–Irinotecan conjugate , 2007 .
[55] T. Berg,et al. Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. , 1992, The Journal of biological chemistry.
[56] V. Mukku,et al. Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol* , 1996, The Journal of Biological Chemistry.
[57] R. Mülhaupt,et al. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. , 1999, Bioorganic & medicinal chemistry.
[58] S. Melmed. Medical progress: Acromegaly. , 2006, The New England journal of medicine.
[59] M. Vellard. The enzyme as drug: application of enzymes as pharmaceuticals. , 2003, Current opinion in biotechnology.
[60] H. Tanaka,et al. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. , 1991, Cancer research.
[61] T. Ulich,et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.
[62] Y. Ikada,et al. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.
[63] J S Beckman,et al. Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. , 1989, The American journal of physiology.
[64] B. Shin,et al. Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. , 2004, Chemical & pharmaceutical bulletin.
[65] Astrid A. Ortiz,et al. A Novel Long-Acting Selective Neuropeptide Y2 Receptor Polyethylene Glycol-Conjugated Peptide Agonist Reduces Food Intake and Body Weight and Improves Glucose Metabolism in Rodents , 2007, Journal of Pharmacology and Experimental Therapeutics.
[66] Richard B Greenwald,et al. Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.
[67] M. Bentley,et al. 722 POSTER Antitumor activity and pharmacokinetics of a novel PEGylated irinotecan in irinotecan-resistant colorectal tumours implanted in mice , 2007 .
[68] F. Veronese,et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. , 2005, Bioconjugate chemistry.
[69] N. Janjić,et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.
[70] J. Kopchick,et al. Clinical review 166: Growth hormone receptor antagonists. , 2004, The Journal of clinical endocrinology and metabolism.
[71] J. Kopchick,et al. Growth hormone receptor antagonists. , 2002, Minerva endocrinologica.
[72] T. Palm,et al. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis. , 2006, Bioconjugate chemistry.
[73] R. Hirschhorn. Adenosine deaminase deficiency: molecular basis and recent developments. , 1995, Clinical immunology and immunopathology.
[74] A. Schacher,et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). , 2003, Protein expression and purification.
[75] M. Nucci,et al. Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase. , 1986, Journal of free radicals in biology & medicine.
[76] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[77] Y. Byun,et al. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice , 2006, Diabetologia.
[78] M. S. Tewart,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .
[79] Durand Woodman,et al. Meeting of the American Chemical Society , 1898, Science.
[80] F. Davis,et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.
[81] J. Kopchick,et al. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. , 2004, The Journal of clinical endocrinology and metabolism.
[82] Mariangela Spitali,et al. Therapeutic antibody fragments with prolonged in vivo half-lives , 1999, Nature Biotechnology.
[83] J. Bomalaski,et al. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.
[84] Y. Youn,et al. Intranasal Delivery of PEGylated Salmon Calcitonins: Hypocalcemic Effects in Rats , 2003, Calcified Tissue International.
[85] E. Frenkel,et al. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation. , 2003, Cancer research.
[86] oseph,et al. PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .